Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
Kazuo Fujihara, Noriko Isobe, Katsuichi Miyamoto, Masaaki Niino, Jin Nakahara, Satoshi Hattori, Mamoru Yamamoto, Izumi Kawachi, Naoko Matsui, Chiyoko Nohara, Norito Kokubun, Norio Chihara, Tatsuro Misu, Kazumasa Okada, Katsuhisa Yamashita, Tadashi Nagatsuka, Hiroki Adachi, Ichiro Nakashim. Effectiveness of satralizumab in a real-world clinical setting in Japan: Interleukin-6 receptor inhibition in neuromyelitis optica spectrum disorder: A six-month interim analysis of a multicenter medical chart review. Multiple sclerosis and related disorders. vol 98. 2025-04-09. PMID:40203604. |
satralizumab is approved in japan for relapse prevention of neuromyelitis optica spectrum disorder (nmosd) in aquaporin-4 immunoglobulin g-seropositive (aqp4[+]) patients. |
2025-04-09 |
2025-04-12 |
Not clear |
Marjo S van der Knaap, Rogier Mi. Multiple sclerosis: an immune attack on astrocyte-mediated ion and water homeostasis. Nature reviews. Neurology. 2025-04-04. PMID:40186039. |
autoimmunity against aqp4 underlies another demyelinating disorder, neuromyelitis optica, and autoimmunity against kir4.1 has been implicated in a subtype of ms. genetic defects in any of these proteins cause leukodystrophies with disruption of brain ion and water homeostasis, which is regulated by astrocytes and secondarily affects myelin. |
2025-04-04 |
2025-04-08 |
Not clear |
Linjie Zhang, Alexei Verkhratsky, Fu-Dong Sh. Astrocytes and microglia in multiple sclerosis and neuromyelitis optica. Handbook of clinical neurology. vol 210. 2025-03-27. PMID:40148041. |
in neuromyelitis optica, autoantibodies against water channel aquaporin 4 (aqp4), which are localized at astrocytic endfeet mediate damage of the glia limitans thus facilitating infiltration of blood-borne molecules and cells that propagate the damage to nerves and neurons. |
2025-03-27 |
2025-03-30 |
Not clear |
Takashi Yoshimura, Masakazu Wakai, Takashi Kanbayashi, Masahisa Katsun. [Symptomatic narcolepsy type 2 in a patient with AQP4-positive neuromyelitis optica spectrum disorder]. Rinsho shinkeigaku = Clinical neurology. 2025-03-26. PMID:40139811. |
the patient tested positive for aqp4 antibody, and was diagnosed with neuromyelitis optica spectrum disorder (nmosd). |
2025-03-26 |
2025-03-30 |
Not clear |
Marlen Alisch, Franziska Foersterling, Dario Zocholl, Bakhrom Muinjonov, Patrick Schindler, Ankelien Duchnow, Carolin Otto, Klemens Ruprecht, Tanja Schmitz-Hübsch, Sven Jarius, Friedemann Paul, Volker Siffri. Distinguishing Neuromyelitis Optica Spectrum Disorders Subtypes: A Study on AQP4 and C3d Epitope Expression in Cytokine-Primed Human Astrocytes. Glia. vol 73. issue 5. 2025-03-19. PMID:40103346. |
distinguishing neuromyelitis optica spectrum disorders subtypes: a study on aqp4 and c3d epitope expression in cytokine-primed human astrocytes. |
2025-03-19 |
2025-03-21 |
human |
Biyue Chen, Huanfen Zhou, Mingming Sun, Wanqun Yang, Qianqian Li, Kaishu Yang, Honglu Song, Quangang Xu, Xintong Xu, Yuyu Li, Yanyan Yu, Shihui Wei, Tingjun Che. Intravitreal delivery of NMO-IgG causes primary retinal damage in the absence of optic nerve injury. Journal of neuroinflammation. vol 22. issue 1. 2025-03-08. PMID:40055743. |
neuromyelitis optica (nmo) is a neuroimmune disorder primarily driven by autoantibodies against aquaporin 4 (aqp4), known as nmo-igg. |
2025-03-08 |
2025-03-12 |
Not clear |
Ali Maisam Afzali, Oleksii Ulianov, Luise Eckardt, Ingrid Stas, Lea Seeholzer, Katja Steiger, Doron Merkler, Thomas Kor. AQP4-specific T cells determine lesion localization in the CNS in a model of NMOSD. Acta neuropathologica communications. vol 13. issue 1. 2025-02-12. PMID:39934927. |
neuromyelitis optica spectrum disorder (nmosd) is a paradigmatic autoimmune disease of the central nervous system (cns), in which the water channel protein aquaporin-4 (aqp4) is targeted by a self-reactive immune response. |
2025-02-12 |
2025-02-14 |
human |
Ennio Polilli, Paola Volpe, Jessica Elisabetta Esposito, Annalisa Di Risio, Caterina Di Carmine, Giancarlo Di Iorio, Marco Gabini, Pierluigi Tocc. AQP4 antibody-seropositive neuromyelitis optica spectrum disorder in a patient with mixed connective tissue disease: a case report. AME case reports. vol 9. 2025-01-27. PMID:39866260. |
aqp4 antibody-seropositive neuromyelitis optica spectrum disorder in a patient with mixed connective tissue disease: a case report. |
2025-01-27 |
2025-01-29 |
Not clear |
Tadele Eticha, Mingqin Zhu, Zhiyong Dong, Solomon Sime Tessema, Ala'a Mhmoued Abdllh Alboull, Di Ma, Guobao X. Single-electrode electrochemiluminescence immunosensor for multiplex detection of Aquaporin-4 antibody using metal-organic gels as coreactant. Biosensors & bioelectronics. vol 272. 2025-01-20. PMID:39764981. |
reliable detection of aquaporin-4 (aqp4) antibodies is crucial for diagnosing neuromyelitis optica spectrum disorder (nmosd). |
2025-01-20 |
2025-01-23 |
Not clear |
Wenjing Yang, Pei Chen, Jiaxuan Guo, Huiyu Feng, Xin Huan. Clinical efficacy of efgartigimod combined with intravenous methylprednisolone in the acute phase of neuromyelitis optica spectrum disorders. Orphanet journal of rare diseases. vol 19. issue 1. 2024-12-21. PMID:39709432. |
neuromyelitis optica spectrum disorders (nmosd) comprise a group of autoimmune-mediated, inflammatory, demyelinating central nervous system diseases caused by aquaporin-4 (aqp4) igg autoantibodies. |
2024-12-21 |
2024-12-24 |
human |
Binbin Xue, Jia Li, Dewei Xie, Yiyun Weng, Xu Zhang, Xiang Li, Junhui Xia, Jie Li. Effects of early intervention in neuromyelitis optica spectrum disorder patients with seropositive AQP4 antibodies. Frontiers in immunology. vol 15. 2024-11-18. PMID:39555058. |
effects of early intervention in neuromyelitis optica spectrum disorder patients with seropositive aqp4 antibodies. |
2024-11-18 |
2024-11-22 |
Not clear |
Yingjie Hua, Andi Xu, Huifen Huang, Shuiwei Xia, Junlin Chen, Siyu Lu, Xufang Huang, Zhongwei Zhao, Dan W. Aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder triggered by herpes zoster: a case report and literature review. The Journal of international medical research. vol 52. issue 11. 2024-11-14. PMID:39539187. |
this paper presents the case of a 45-year-old woman who developed aquaporin-4 (aqp4) antibody-positive neuromyelitis optica spectrum disorder (nmosd) approximately 6 weeks after a herpes zoster infection. |
2024-11-14 |
2024-11-17 |
Not clear |
Claudia Chien, Vera Cruz E Silva, Emanuel Geiter, Dominik Meier, Hanna Zimmermann, Denis B Bichuetti, Marcos I Idagawa, Ayse Altintas, Uygur Tanriverdi, Sasitorn Siritho, Lehka Pandit, Anitha Dcunha, Maria J Sá, Rita Figueiredo, Peiqing Qian, Caryl Tongco, Itay Lotan, Vadim Khasminsky, Mark A Hellmann, Hadas Stiebel-Kalish, Dalia L Rotstein, Lindsay Waxman, Daniel Ontaneda, Kunio Nakamura, Hesham Abboud, M Omar Subei, Yang Mao-Draayer, Joachim Havla, Nasrin Asgari, Pernille B Skejø, Ilya Kister, Marius Ringelstein, Simon Broadley, Simon Arnett, Brie Marron, Anna M Jolley, Michael Wunderlich, Sean Green, Lawrence J Cook, Michael R Yeaman, Terry J Smith, Alexander U Brandt, Jens Wuerfel, Friedemann Pau. Aquaporin-4 Immunoglobulin G-seropositive Neuromyelitis Optica Spectrum Disorder MRI Characteristics: Data Analysis from the International Real-World PAMRINO Study Cohort. Radiology. vol 313. issue 2. 2024-11-12. PMID:39530897. |
background patients with neuromyelitis optica spectrum disorder (nmosd) are often seropositive for antibodies against aquaporin-4 (aqp4). |
2024-11-12 |
2024-11-17 |
Not clear |
Mitsuru Watanabe, Noriko Isobe, Masaaki Niino, Ichiro Nakashima, Takuya Matsushita, Yasunari Sakai, Jin Nakahara, Izumi Kawachi, Hirofumi Ochi, Yuji Nakatsuji, Yosikazu Nakamura, Koshi Nakamura, Kiyomi Sakata, Makoto Matsui, Satoshi Kuwabara, Jun-Ichi Kir. Prevalence of, and Disability Due to, Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in Japan by the Fifth Nationwide Survey. Neurology. vol 103. issue 10. 2024-10-30. PMID:39475688. |
all 4 previous nationwide surveys of multiple sclerosis (ms) in japan were conducted before the discovery of anti-aquaporin-4 (aqp4) antibodies; thus, neuromyelitis optica spectrum disorder (nmosd) was included in ms, as optic-spinal ms. we aimed to clarify the epidemiologic features and trends of ms and nmosd in japan separately using a fifth nationwide survey. |
2024-10-30 |
2024-11-02 |
Not clear |
Jonathan D Krett, Angeliki G Filippatou, Paula Barreras, Carlos A Pardo, Allan C Gelber, Elias S Sotircho. "Lupus Myelitis" Revisited: A Retrospective Single-Center Study of Myelitis Associated With Rheumatologic Disease. Neurology(R) neuroimmunology & neuroinflammation. vol 12. issue 1. 2024-10-23. PMID:39442039. |
previous reports of patients with myelitis associated with rheumatologic disease may have had unrecognized aquaporin-4 (aqp4)-igg seropositive neuromyelitis optica spectrum disorder (nmosd) or myelin oligodendrocyte glycoprotein (mog)-igg-associated disease (mogad). |
2024-10-23 |
2024-10-26 |
Not clear |
Akiyuki Uzawa, Frederike Cosima Oertel, Masahiro Mori, Friedemann Paul, Satoshi Kuwabar. NMOSD and MOGAD: an evolving disease spectrum. Nature reviews. Neurology. 2024-09-13. PMID:39271964. |
neuromyelitis optica (nmo) spectrum disorder (nmosd) is a relapsing inflammatory disease of the cns, characterized by the presence of serum aquaporin 4 (aqp4) autoantibodies (aqp4-iggs) and core clinical manifestations such as optic neuritis, myelitis, and brain or brainstem syndromes. |
2024-09-13 |
2024-09-16 |
Not clear |
Sydney Lee, Ruth Ann Marrie, Giulia Fadda, Mark S Freedman, Liesly Lee, Alexandra Muccilli, Manav V Vyas, Andrea Konig, Dalia L Rotstei. Is there a prodrome to NMOSD? An investigation of neurologic symptoms preceding the first NMOSD attack. Multiple sclerosis (Houndmills, Basingstoke, England). 2024-09-11. PMID:39258406. |
it is unknown whether people with aquaporin-4 antibody positive (aqp4-igg+) neuromyelitis optica spectrum disorder (nmosd) experience a prodrome, although a few cases report aqp4 + serology up to 16 years before the first attack. |
2024-09-11 |
2024-09-13 |
Not clear |
Yuan Cao, Wen Yao, Fang Che. Brief research report: WGCNA-driven identification of histone modification genes as potential biomarkers in AQP4-Associated optic neuritis. Frontiers in genetics. vol 15. 2024-09-06. PMID:39238786. |
neuromyelitis optica spectrum disorder (nmosd) is an autoimmune disease characterized by anti-aquaporin-4 (aqp4) auto-antibodies. |
2024-09-06 |
2024-09-08 |
Not clear |
Yuan Cao, Wen Yao, Fang Che. Brief research report: WGCNA-driven identification of histone modification genes as potential biomarkers in AQP4-Associated optic neuritis. Frontiers in genetics. vol 15. 2024-09-06. PMID:39238786. |
the discovery of antibodies aqp4 and myelin oligodendrocyte glycoprotein (mog) has expanded our understanding of the pathogenesis of neuromyelitis optica. |
2024-09-06 |
2024-09-08 |
Not clear |
Chihiro Namatame, Yoichiro Abe, Yoshiki Miyasaka, Yoshiki Takai, Yuki Matsumoto, Toshiyuki Takahashi, Tomoji Mashimo, Tatsuro Misu, Kazuo Fujihara, Masato Yasui, Masashi Aok. Humanized-Aquaporin-4-Expressing Rat Created by Gene-Editing Technology and Its Use to Clarify the Pathology of Neuromyelitis Optica Spectrum Disorder. International journal of molecular sciences. vol 25. issue 15. 2024-08-10. PMID:39125739. |
conventional rodent neuromyelitis optica spectrum disorder (nmosd) models using patient-derived immunoglobulin g (igg) are potentially affected by the differences between the human and rodent aquaporin-4 (aqp4) extracellular domains (ecds). |
2024-08-10 |
2024-08-13 |
human |